Developer docs
API playgroundTry for free, no card

Search company profiles

Sonio

Full company profile

uuid0000p1y

Namestring
Sonio
Legal namestring
Sonio SAS
Websiteurl
sonio.ai
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Sonio is a Paris-based, AI-powered SaaS company founded in April 2020 that standardizes and automates fetal ultrasound workflows for obstetricians, maternal-fetal medicine (MFM) specialists, sonographers, and women's health organizations. Its cloud-native platform combines reporting, image management, DICOM worklist handling, HL7/FHIR-based EMR and billing integration, PACS/VNA connectivity, visual exam checklists, and practice analytics, sold under a vendor-agnostic model compatible with all ultrasound manufacturers. The company's AI layer includes Sonio Detect (FDA 510(k)-cleared view and anatomical structure detection, now in version 3), Sonio Suspect (FDA 510(k)-cleared anomaly detection across heart, brain, and abdomen), and Sonio Voice (real-time AI-driven voice transcription of ultrasound findings). Sonio has secured five FDA 510(k) clearances, ISO 13485 certification, CE marking, SOC 2 Type 2, HIPAA, and HDS compliance, and was acquired by Samsung Medison in September 2024 while continuing to operate independently and sell across all ultrasound OEMs.

The company monetizes primarily through enterprise SaaS subscriptions sold via direct field sales, with custom quote-based pricing tied to facility size and AI module requirements. Customer segments span OB-GYN and MFM practices, women's health MSOs, academic medical centers, community medical centers, and SMB midwife-sonographer users. Named customers include Pediatrix Medical Group (first US customer, Jan 2024), HCA Healthcare, Genesis, GW MFM, Calla Perinatal, WHASN, TLC Perinatal, DPA, and NJPA, with deployment in over 100 US clinics within two years of first US signing. Distribution in international markets is enabled through channel partners in India (MFine/Lifecell), Brazil (Manager Systems), Nigeria (Dynamic Medical Engineering), and Portugal (Astrimed), alongside an OEM embedding channel opened by the June 2026 Sonio Suspect Integration Configuration FDA clearance. As of the latest data, Sonio operates with 59 employees across Paris, New York, and Cambridge, MA, with the CEO relocated to Boston and a dedicated US Director of Operations.

Short descriptiontext

Sonio is a Paris-based AI SaaS company, acquired by Samsung Medison in 2024, that provides a cloud-native fetal ultrasound reporting and image-management platform with FDA-cleared AI modules for view detection and anomaly detection, serving OB-GYN and maternal-fetal medicine practices across 100+ US clinics and international channel-partner markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fetal ultrasound software, prenatal imaging AI, OB-GYN reporting software, medical imaging AI, cloud healthcare platform
Industry2 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code2 codes
  • Medical Laboratories621511
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Prepackaged Software7372
Product category
Healthcare AI Software - Fetal Ultrasound Reporting and Imaging
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1SaaS Subscriptions - Sonio Platform
TypeSubscription Recurring
Description

Cloud-based subscription software for OB-GYN ultrasound reporting and image management. Pricing based on facility/practice level with tiered plans. Revenue generated from annual or multi-year subscriptions.

sonio.ai
2Sonio Detect (AI Medical Device)
TypeSubscription Recurring
Description

FDA 510(k) cleared AI software module. Sold as part of platform subscription or potentially as separate module. Revenue recognized as part of overall SaaS platform.

sonio.ai
3Sonio Suspect (AI Anomaly Detection)
TypeSubscription Recurring
Description

FDA 510(k) cleared AI module for anomaly detection. Integrated into Sonio platform, generating revenue through platform subscription model.

sonio.ai
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Custom enterprise pricing based on facility size and requirements
ModelSubscriptionBilling cadenceAnnual
Notes

No public pricing available; 'Request a Demo' CTA implies enterprise sales motion with custom pricing. Volume and feature tiers likely based on practice size and AI module requirements.

sonio.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Sonio Detect
Description

FDA 510(k) cleared AI product that empowers ultrasound practitioners to perform routine fetal ultrasound examinations with automatic view detection, anatomical structure detection, and quality criteria verification.

sonio.ai
+4 more records
Core offering1 text field

Sonio develops a cloud-native AI-powered SaaS platform that standardizes and automates fetal ultrasound workflows, from image acquisition and reporting to quality review and billing handoff. The offering combines FDA 510(k) cleared AI modules (Sonio Detect for view/structure detection and quality control, Sonio Suspect for anomaly detection, Sonio Voice for real-time voice transcription) with an OB/GYN reporting SaaS (Sonio Pro) integrated via HL7, FHIR, and DICOM into existing EMR, PACS, and billing systems at OB-GYN and Maternal-Fetal Medicine practices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 22-point improvement in anomaly detection performance (69% to 91% AUC) demonstrated in multicenter reader study across 47 sites
+6 more records
Product overview1 text field

Sonio offers a cloud-native AI-powered prenatal ultrasound platform with two main product tiers: Sonio Pro (core reporting and workflow SaaS) and add-on AI modules Sonio Detect (quality assurance, view/structure detection) and Sonio Suspect (anomaly detection), all integrated within the unified Sonio Platform. Sonio Voice adds AI-powered voice-driven data input. The architecture is machine-agnostic and interoperable, supporting all ultrasound manufacturers and integrating with EMR, PACS, and billing systems via HL7, FHIR, and DICOM.

Product and service6 records
1Sonio Platform
CategoryCore platform
Description

Secure, cloud-native AI-powered platform that standardizes and automates fetal ultrasound workflows from image acquisition and reporting to quality review and billing handoff. Integrates with all ultrasound manufacturers and supports HL7, FHIR, and DICOM interoperability for OB-GYN and Maternal-Fetal Medicine practices.

2Sonio Pro
CategoryReporting SaaS
Description

SaaS solution for OB/GYN exams that receives and uploads media from ultrasound equipment in DICOM format, acts as a modality worklist for ultrasound equipment, and interacts with EMR and billing systems through HL7. Includes report templates, image management, visual checklist, sharing, and practice analytics modules.

3Sonio Detect
CategoryAI quality assurance module
Description

FDA 510(k) cleared and CE-marked AI module that empowers ultrasound practitioners to perform fetal ultrasound examinations in real time by automatically detecting views, identifying anatomical structures (brain, thorax, heart, placenta), and verifying image quality criteria against standardized protocols.

4Sonio Suspect
CategoryAI anomaly detection module
Description

FDA 510(k) cleared AI module for prenatal screening with automatic detection of eight abnormal findings across seven ultrasound views of three fetal anatomical regions (heart, brain, abdomen). Demonstrated a 22-point improvement in reader performance (69% to 91% AUC) across 47 sites in a multicenter reader study.

5Sonio Voice
CategoryAI voice workflow module
Description

AI-powered voice solution integrated with Sonio's ultrasound reporting software that transcribes, interprets, and inputs ultrasound data in real time as sonographers perform exams, converting spoken clinical observations into structured report entries to optimize workflow and reduce administrative burden.

6soniopedia
CategoryEducational bioinformatic tool
Description

Educational bioinformatic tool for prenatal diagnosis experts that enables users to identify syndromes based on initial ultrasound phenotypes through interactive prenatal diagnosis quizzes. Launched at FMF World Congress 2024 in Lisbon, Portugal.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-02
Description

Acquisition by Samsung Medison in September 2024 following approval by French Ministry of Economy and Finance. Strategic move to accelerate global growth in maternal care and combine Sonio's AI-driven solutions with Samsung's engineering expertise. Sonio continues commercial operations independently while developing products compatible with all ultrasound manufacturers. Deal enables expansion of ultrasound technology portfolio including next-generation AI products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing collaboration with world-renowned children's hospital in Paris, founded in 1802. Multiple Sonio co-founders are affiliated with Necker. Partnership provides clinical validation, research collaboration, and medical expertise for product development.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership announced March 2023 to expand Sonio's AI-powered technology in India, a market experiencing increasing demand for advanced medical solutions. MFine is a digital health platform serving millions of patients. Partnership aims to improve accuracy and reliability of pregnancy ultrasound scans in India.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner in Brazil since 1988, focused on delivering quality management of medical services to practitioners and patients across Brazil.

5Dynamic Medical Engineering Company (Nigeria)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner in Nigeria with mission to improve women's and children's health through technological innovation. General Manager Raymond Okosun runs laboratory for newborn screening, non-invasive prenatal screening, and maternal risk assessments.

sonio.ai
6Astrimed (Portugal)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner in Portugal since 2004, dedicated to delivering products and services of highest quality for health systems. Expertise in marketing and supporting medical software and equipment across hospitals, clinics, and practitioners.

sonio.ai
Strategic tierCoreTypeTechnology or Integration
Description

Technical partnership with globally renowned institution excelling in science, engineering, and research. Pr. Erwan Le Pennec from Applied Mathematics at École Polytechnique serves on Scientific Advisory Board.

Strategic tierCoreTypeTechnology or Integration
Description

Research institute and innovation center driving AI and machine learning progress. Partnership supports Sonio's AI development capabilities.

Strategic tierCoreTypeTechnology or Integration
Description

Initial partnership announced September 2021 joining Samsung Healthcare ecosystem. Confirmed innovative nature of AI solutions dedicated to securing pregnancy monitoring and optimizing prenatal diagnosis. Preceded acquisition by Samsung Medison.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in ultrasound (Voluson) and AI-powered imaging. Directly competes with Sonio's AI modules through its own ultrasound AI initiatives (including Caption Health acquisition) and has overlapping target customers in OB-GYN and MFM practices.

TypeEmerging player
Description

AI echocardiography platform (FDA-cleared) for cardiac function analysis. Comparable as a focused AI ultrasound SaMD company pursuing specialty diagnostic use cases with regulatory clearances and cloud delivery.

TypeBroad incumbent
Description

Ultrasound OEM (ACUSON) with AI-augmented imaging capabilities and integrated OB/GYN workflows. Comparable through direct ultrasound hardware sales plus AI features and shared MFM customer base.

4Caption Health (GE HealthCare)
TypeEmerging player
Description

AI guidance software for ultrasound acquisition (initially cardiac, expanding to broader point-of-care). Acquired by GE HealthCare in 2023; directly comparable as AI ultrasound SaaS that helps less experienced users capture diagnostic-quality exams.

TypeEmerging player
Description

Portable, AI-enabled ultrasound platform with cloud-based workflow software. Comparable as a connected ultrasound + AI SaaS play, though more focused on point-of-care than OB-GYN specialty.

TypeBroad incumbent
Description

Parent company of Sonio since September 2024 and a leading OB-GYN ultrasound OEM (HERA W10). Closest incumbent peer given direct ownership relationship and overlapping product/portfolio strategy.

TypeDirect peer
Description

AI software for obstetric and vascular ultrasound, including automated detection, measurements, and reporting. Closest direct competitor in AI-driven fetal/obstetric ultrasound workflows and reporting automation.

TypeEmerging player
Description

AI-based clinical decision support for medical imaging (breast, thyroid, prostate) with FDA-cleared SaMD products. Comparable as a specialty AI imaging SaMD vendor with similar go-to-market in clinical practices.

TypeRegional player
Description

China-based ultrasound OEM with growing global presence and embedded AI capabilities in OB-GYN imaging. Comparable as ultrasound manufacturer competing in MFM/OB-GYN market with bundled AI features.

TypeBroad incumbent
Description

Major ultrasound manufacturer (Philips EPIQ, Affiniti) with growing AI-based obstetrics and radiology tools. Comparable as a full-stack ultrasound + AI/saMD competitor in OB-GYN and MFM markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sonio

Healthcare AI Software - Fetal Ultrasound Reporting and Imagingsonio.ai

Sonio is a Paris-based AI SaaS company, acquired by Samsung Medison in 2024, that provides a cloud-native fetal ultrasound reporting and image-management platform with FDA-cleared AI modules for view detection and anomaly detection, serving OB-GYN and maternal-fetal medicine practices across 100+ US clinics and international channel-partner markets.

What Sonio does

Sonio is a Paris-based, AI-powered SaaS company founded in April 2020 that standardizes and automates fetal ultrasound workflows for obstetricians, maternal-fetal medicine (MFM) specialists, sonographers, and women's health organizations. Its cloud-native platform combines reporting, image management, DICOM worklist handling, HL7/FHIR-based EMR and billing integration, PACS/VNA connectivity, visual exam checklists, and practice analytics, sold under a vendor-agnostic model compatible with all ultrasound manufacturers. The company's AI layer includes Sonio Detect (FDA 510(k)-cleared view and anatomical structure detection, now in version 3), Sonio Suspect (FDA 510(k)-cleared anomaly detection across heart, brain, and abdomen), and Sonio Voice (real-time AI-driven voice transcription of ultrasound findings). Sonio has secured five FDA 510(k) clearances, ISO 13485 certification, CE marking, SOC 2 Type 2, HIPAA, and HDS compliance, and was acquired by Samsung Medison in September 2024 while continuing to operate independently and sell across all ultrasound OEMs.

The company monetizes primarily through enterprise SaaS subscriptions sold via direct field sales, with custom quote-based pricing tied to facility size and AI module requirements. Customer segments span OB-GYN and MFM practices, women's health MSOs, academic medical centers, community medical centers, and SMB midwife-sonographer users. Named customers include Pediatrix Medical Group (first US customer, Jan 2024), HCA Healthcare, Genesis, GW MFM, Calla Perinatal, WHASN, TLC Perinatal, DPA, and NJPA, with deployment in over 100 US clinics within two years of first US signing. Distribution in international markets is enabled through channel partners in India (MFine/Lifecell), Brazil (Manager Systems), Nigeria (Dynamic Medical Engineering), and Portugal (Astrimed), alongside an OEM embedding channel opened by the June 2026 Sonio Suspect Integration Configuration FDA clearance. As of the latest data, Sonio operates with 59 employees across Paris, New York, and Cambridge, MA, with the CEO relocated to Boston and a dedicated US Director of Operations.

Sonio firmographics

Firmographics
Name
Sonio
Legal name
Sonio SAS
Website
https://sonio.ai
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
Sonio is a Paris-based AI SaaS company, acquired by Samsung Medison in 2024, that provides a cloud-native fetal ultrasound reporting and image-management platform with FDA-cleared AI modules for view detection and anomaly detection, serving OB-GYN and maternal-fetal medicine practices across 100+ US clinics and international channel-partner markets.
Ownership category
akta.pro rank

Sonio industry classification

Industry
Product category
Healthcare AI Software - Fetal Ultrasound Reporting and Imaging
NAICS
Medical Laboratories (621511), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • Fetal ultrasound software
  • Prenatal imaging AI
  • OB-GYN reporting software
  • Medical imaging AI
  • Cloud healthcare platform

Where Sonio is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Sonio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. SaaS Subscriptions - Sonio Platform: Cloud-based subscription software for OB-GYN ultrasound reporting and image management. Pricing based on facility/practice level with tiered plans. Revenue generated from annual or multi-year subscriptions.
  2. Sonio Detect (AI Medical Device): FDA 510(k) cleared AI software module. Sold as part of platform subscription or potentially as separate module. Revenue recognized as part of overall SaaS platform.
  3. Sonio Suspect (AI Anomaly Detection): FDA 510(k) cleared AI module for anomaly detection. Integrated into Sonio platform, generating revenue through platform subscription model.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualCustom enterprise pricing based on facility size and requirements

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Sonio product offering

Product offering

Core offering

Sonio develops a cloud-native AI-powered SaaS platform that standardizes and automates fetal ultrasound workflows, from image acquisition and reporting to quality review and billing handoff. The offering combines FDA 510(k) cleared AI modules (Sonio Detect for view/structure detection and quality control, Sonio Suspect for anomaly detection, Sonio Voice for real-time voice transcription) with an OB/GYN reporting SaaS (Sonio Pro) integrated via HL7, FHIR, and DICOM into existing EMR, PACS, and billing systems at OB-GYN and Maternal-Fetal Medicine practices.

Product overview

Sonio offers a cloud-native AI-powered prenatal ultrasound platform with two main product tiers: Sonio Pro (core reporting and workflow SaaS) and add-on AI modules Sonio Detect (quality assurance, view/structure detection) and Sonio Suspect (anomaly detection), all integrated within the unified Sonio Platform. Sonio Voice adds AI-powered voice-driven data input. The architecture is machine-agnostic and interoperable, supporting all ultrasound manufacturers and integrating with EMR, PACS, and billing systems via HL7, FHIR, and DICOM.

Differentiator

Problem solved

Functional benefit

Brands

  • Sonio Detect: FDA 510(k) cleared AI product that empowers ultrasound practitioners to perform routine fetal ultrasound examinations with automatic view detection, anatomical structure detection, and quality criteria verification.
  • Sonio Pro
  • Sonio Suspect
  • Sonio Voice
  • soniopedia

Products and services

  • Sonio Platform Secure, cloud-native AI-powered platform that standardizes and automates fetal ultrasound workflows from image acquisition and reporting to quality review and billing handoff. Integrates with all ultrasound manufacturers and supports HL7, FHIR, and DICOM interoperability for OB-GYN and Maternal-Fetal Medicine practices.
  • Sonio Pro SaaS solution for OB/GYN exams that receives and uploads media from ultrasound equipment in DICOM format, acts as a modality worklist for ultrasound equipment, and interacts with EMR and billing systems through HL7. Includes report templates, image management, visual checklist, sharing, and practice analytics modules.
  • Sonio Detect FDA 510(k) cleared and CE-marked AI module that empowers ultrasound practitioners to perform fetal ultrasound examinations in real time by automatically detecting views, identifying anatomical structures (brain, thorax, heart, placenta), and verifying image quality criteria against standardized protocols.
  • Sonio Suspect FDA 510(k) cleared AI module for prenatal screening with automatic detection of eight abnormal findings across seven ultrasound views of three fetal anatomical regions (heart, brain, abdomen). Demonstrated a 22-point improvement in reader performance (69% to 91% AUC) across 47 sites in a multicenter reader study.
  • Sonio Voice AI-powered voice solution integrated with Sonio's ultrasound reporting software that transcribes, interprets, and inputs ultrasound data in real time as sonographers perform exams, converting spoken clinical observations into structured report entries to optimize workflow and reduce administrative burden.
  • soniopedia Educational bioinformatic tool for prenatal diagnosis experts that enables users to identify syndromes based on initial ultrasound phenotypes through interactive prenatal diagnosis quizzes. Launched at FMF World Congress 2024 in Lisbon, Portugal.

Quantifiable outcome

  • 22-point improvement in anomaly detection performance (69% to 91% AUC) demonstrated in multicenter reader study across 47 sites
  • +6 more outcomes

Companies that use Sonio

Customer profile

Named customers12 records

Segments8 records

Ideal customer profiles2 records

Sonio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability7 records

Feature6 records

Sonio partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered flagship, core and regional.

  • Samsung MedisonflagshipStrategic or Co-development Partner · 2 September 2024Acquisition by Samsung Medison in September 2024 following approval by French Ministry of Economy and Finance. Strategic move to accelerate global growth in maternal care and combine Sonio's AI-driven solutions with Samsung's engineering expertise. Sonio continues commercial operations independently while developing products compatible with all ultrasound manufacturers. Deal enables expansion of ultrasound technology portfolio including next-generation AI products.
  • Necker-Enfants Malades University HospitalcoreStrategic or Co-development PartnerLong-standing collaboration with world-renowned children's hospital in Paris, founded in 1802. Multiple Sonio co-founders are affiliated with Necker. Partnership provides clinical validation, research collaboration, and medical expertise for product development.
  • MFine (Lifecell)regionalChannel Partner/ Reseller/ DistributorDistribution partnership announced March 2023 to expand Sonio's AI-powered technology in India, a market experiencing increasing demand for advanced medical solutions. MFine is a digital health platform serving millions of patients. Partnership aims to improve accuracy and reliability of pregnancy ultrasound scans in India.
  • Manager Systems (Brazil)regionalChannel Partner/ Reseller/ DistributorDistribution partner in Brazil since 1988, focused on delivering quality management of medical services to practitioners and patients across Brazil.
  • Dynamic Medical Engineering Company (Nigeria)regionalChannel Partner/ Reseller/ DistributorDistribution partner in Nigeria with mission to improve women's and children's health through technological innovation. General Manager Raymond Okosun runs laboratory for newborn screening, non-invasive prenatal screening, and maternal risk assessments.
  • Astrimed (Portugal)regionalChannel Partner/ Reseller/ DistributorDistribution partner in Portugal since 2004, dedicated to delivering products and services of highest quality for health systems. Expertise in marketing and supporting medical software and equipment across hospitals, clinics, and practitioners.
  • École PolytechniquecoreTechnology or IntegrationTechnical partnership with globally renowned institution excelling in science, engineering, and research. Pr. Erwan Le Pennec from Applied Mathematics at École Polytechnique serves on Scientific Advisory Board.
  • PrairiecoreTechnology or IntegrationResearch institute and innovation center driving AI and machine learning progress. Partnership supports Sonio's AI development capabilities.
  • Samsung Healthcare FrancecoreTechnology or IntegrationInitial partnership announced September 2021 joining Samsung Healthcare ecosystem. Confirmed innovative nature of AI solutions dedicated to securing pregnancy monitoring and optimizing prenatal diagnosis. Preceded acquisition by Samsung Medison.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Sonio competitors and assessment

Company assessment

Broad incumbents

  • GE HealthCare: Global leader in ultrasound (Voluson) and AI-powered imaging. Directly competes with Sonio's AI modules through its own ultrasound AI initiatives (including Caption Health acquisition) and has overlapping target customers in OB-GYN and MFM practices.
  • Siemens Healthineers: Ultrasound OEM (ACUSON) with AI-augmented imaging capabilities and integrated OB/GYN workflows. Comparable through direct ultrasound hardware sales plus AI features and shared MFM customer base.
  • Samsung Medison: Parent company of Sonio since September 2024 and a leading OB-GYN ultrasound OEM (HERA W10). Closest incumbent peer given direct ownership relationship and overlapping product/portfolio strategy.
  • Philips: Major ultrasound manufacturer (Philips EPIQ, Affiniti) with growing AI-based obstetrics and radiology tools. Comparable as a full-stack ultrasound + AI/saMD competitor in OB-GYN and MFM markets.

Emerging players

  • Ultromics: AI echocardiography platform (FDA-cleared) for cardiac function analysis. Comparable as a focused AI ultrasound SaMD company pursuing specialty diagnostic use cases with regulatory clearances and cloud delivery.
  • Caption Health (GE HealthCare): AI guidance software for ultrasound acquisition (initially cardiac, expanding to broader point-of-care). Acquired by GE HealthCare in 2023; directly comparable as AI ultrasound SaaS that helps less experienced users capture diagnostic-quality exams.
  • Butterfly Network: Portable, AI-enabled ultrasound platform with cloud-based workflow software. Comparable as a connected ultrasound + AI SaaS play, though more focused on point-of-care than OB-GYN specialty.
  • Koios Medical: AI-based clinical decision support for medical imaging (breast, thyroid, prostate) with FDA-cleared SaMD products. Comparable as a specialty AI imaging SaMD vendor with similar go-to-market in clinical practices.

Direct peers

  • See-Mode Technologies: AI software for obstetric and vascular ultrasound, including automated detection, measurements, and reporting. Closest direct competitor in AI-driven fetal/obstetric ultrasound workflows and reporting automation.

Regional players

  • Mindray: China-based ultrasound OEM with growing global presence and embedded AI capabilities in OB-GYN imaging. Comparable as ultrasound manufacturer competing in MFM/OB-GYN market with bundled AI features.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Sonio social profiles

Digital presence

Sonio compliance and trust

Trust signal

Compliance5 records

Sonio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sonio leadership team

Management profile

Number of profiles

Profiles12 records

Sonio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sonio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sonio

What does Sonio do?

Sonio develops a cloud-native AI-powered SaaS platform that standardizes and automates fetal ultrasound workflows, from image acquisition and reporting to quality review and billing handoff. The offering combines FDA 510(k) cleared AI modules (Sonio Detect for view/structure detection and quality control, Sonio Suspect for anomaly detection, Sonio Voice for real-time voice transcription) with an OB/GYN reporting SaaS (Sonio Pro) integrated via HL7, FHIR, and DICOM into existing EMR, PACS, and billing systems at OB-GYN and Maternal-Fetal Medicine practices.

Is Sonio a public or private company?

Sonio is a private company. It is classified as corporate owned and is currently operating.

When was Sonio founded?

Sonio was founded in 2020. It employs 101 to 250 people.

Where is Sonio based?

Sonio is headquartered in Boston, United States, in the North America region.

How does Sonio make money?

Three revenue lines are on record. SaaS Subscriptions - Sonio Platform is the primary driver. The others are sonio Detect (AI Medical Device) and sonio Suspect (AI Anomaly Detection).

Who are Sonio's main competitors?

Broad incumbents on record are GE HealthCare, Siemens Healthineers, Samsung Medison and Philips. Emerging players are Ultromics, Caption Health (GE HealthCare), Butterfly Network and Koios Medical. See-Mode Technologies is listed as a direct peer. Mindray is listed as a regional player.

Does Sonio have an API?

No public API is recorded for Sonio.

What industry is Sonio in?

Sonio's product category is Healthcare AI Software - Fetal Ultrasound Reporting and Imaging. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 621511 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Next WebHistoSonics receives TFDA approval in Taiwan for Edison Histotripsy System, accelerating Asia expansionHistoSonics received Taiwan TFDA approval for its Edison Histotripsy System, a non-invasive focused ultrasound device for tumour destruction. The company, valued at $2.25 billion, is expanding in Asia and has submitted a US FDA De Novo application for kidney tumours. It plans to treat over 2,000 patients at more than 50 centres worldwide.EIN Presswire3D Display Market to Hit USD 592.56 Billion by 2032 at 18.8% CAGR | Maximize Market ResearchThe global 3D display market is projected to grow from USD 177.42 billion in 2025 to USD 592.56 billion by 2032, an 18.8% CAGR. North America holds a 29.47% share, while Asia Pacific is the fastest-growing region at 22.26% CAGR. Growth is driven by generative AI, spatial computing, and XR adoption.openPR.comIn-Depth Examination of Segments, Industry Trends, and Key Competitors in the Smart Posture Correction MarketThe Business Research Company published an in-depth market analysis report on the smart posture correction sector, projecting the market to reach $3.47 billion by 2030 with an 18% compound annual growth rate. In August 2024, Samsung Medison Co., Ltd. acquired France-based Sonio, a firm specializing in 3D and 5D ultrasound imaging technologies, to enhance prenatal care outcomes. Additionally, South Korean health tech startup Neurabody launched Posture AI in July 2024, featuring embedded sensors and machine learning analytics to deliver real-time posture correction feedback and predict back pain risks.openPR.comKey Factors and Emerging Trends Shaping the Spectrum Therapy Instrument Market LandscapeThe Business Research Company published a market report projecting the spectrum therapy instrument market to reach $1.73 billion by 2030, growing at a 7.5% compound annual growth rate, driven by rising demand for non-invasive treatments, home-based therapy solutions, and expanded dermatology applications. In August 2024, South Korean diagnostic ultrasound manufacturer Samsung Medison Co., Ltd. acquired France-based Sonio, a 3D and 5D ultrasound device specialist, to strengthen Samsung Medison's presence in healthcare imaging and enhance prenatal care diagnostics. US-based Lumaflex introduced its Lumaflex Essential portable red light therapy device in January 2024, featuring red and near-infrared light technology for home use.openPR.comAnalysis of Segments and Major Growth Areas in the Smart Pills MarketThe smart pills market is projected to reach $10.13 billion by 2030, growing at a compound annual growth rate of 10.7%, driven by demand for personalized medicine, digital therapeutics investments, and remote patient monitoring. In August 2024, Samsung Medison Co., Ltd. completed the acquisition of France-based Sonio, a 3D and 5D ultrasound device manufacturer, to enhance maternal and fetal health outcomes through advanced imaging technology. The Interuniversity Microelectronics Centre in Belgium unveiled an ingestible sensor prototype for gut health monitoring in 2025, featuring chemical, mechanical, and electrical sensing capabilities with real-time data transmission.openPR.comGlobal Factors Shaping the Rapid Evolution of the Temperature Management MarketThe temperature management market is projected to grow from its current size to $3.72 billion by 2030, representing a compound annual growth rate of 5.1%, driven by rising surgical volumes, expanded critical care services, and increased demand for patient warming and cooling systems in hospitals and surgical centers. In August 2024, Samsung Medison Co., Ltd. acquired France-based Sonio, a developer of 3D and 5D ultrasound devices, aiming to integrate advanced fetal imaging technology with maternal healthcare solutions. A separate July 2023 partnership granted ZOLL Medical Corporation exclusive distribution rights for BrainCool's temperature management products across the United States and major European markets.openPR.comTrends in Growth, Segment Analysis, and Competitive Strategies Influencing the Tibial Bearings MarketThe tibial bearings market is projected to grow to $1.91 billion by 2030, with a compound annual growth rate of 8.2%, driven by advancements in medical technology, demand for customized knee implants, robotic-assisted surgeries, and material innovations. In August 2024, Samsung Medison Co., Ltd. completed the acquisition of France-based Sonio to expand its maternal and fetal health imaging portfolio, while MicroPort Orthopaedics launched its Evolution Tibial Cones across North America in September 2024. The report identifies key market players including Stryker Corporation, Zimmer Biomet Holdings Inc., and Smith & Nephew plc, and details segmentation by bearing system type, material, distribution channel, application, and end-user.openPR.comSurgery Tables Market Overview, Current Trends, and Key Player AnalysisThe Business Research Company released an overview of the global surgery tables market, projecting it to reach $1.61 billion by 2030 with a compound annual growth rate of 6.1%. In March 2024, Swedish medical technology company Getinge introduced the Maquet Corin OR table, a smart mobile surgical table featuring collision detection and preset surgical positions. In August 2024, South Korea-based Samsung Medison acquired France-based Sonio, a 3D and 5D ultrasound device specialist, to enhance maternal and fetal health diagnostics.openPR.comAn Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Serum Separation Gel MarketThe global serum separation gel market is projected to reach $13.97 billion by 2030, growing at a compound annual growth rate of 7.4%, driven by increasing demand for advanced laboratory and diagnostic tools, pre-filled gel packs, and wider adoption in pharmaceutical research, blood banking, and large-scale screening programs. In August 2024, Samsung Medison Co. Ltd., a South Korea-based diagnostic ultrasound manufacturer, acquired France-based Sonio, a company specializing in 3D and 5D ultrasound devices, to enhance maternal and fetal health diagnostics by combining Sonio's imaging technology with Samsung's expertise. In May 2023, Greiner Bio-One launched the VACUETTE CAT Serum Fast Separator tube, which reduces blood sample coagulation time to approximately five minutes, reflecting ongoing product innovation in the sector.